GlassScriptPhysician profile
Jocelyn Mckeithan
NPI 1407160484
$5,409.05
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,390 · 2022: $3,675 · 2023: $247 · 2024: $96.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $343.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,045.57 | 2021-2023 | Jakafi |
| Jazz Pharmaceuticals INC. | $923.48 | 2021-2022 | |
| Astellas Pharma US INC | $426.43 | 2021-2024 | Cresemba |
| Glaxosmithkline, LLC. | $382.14 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $270.73 | 2021-2022 | |
| Janssen Biotech, INC. | $266.83 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $232.71 | 2022 | |
| Merck Sharp & Dohme LLC | $211.40 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $169.14 | 2022 | |
| Karyopharm Therapeutics INC. | $160.90 | 2021-2022 | |
| Cti Biopharma Corp. | $151.20 | 2022 | |
| Abbvie INC. | $145.02 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $138.22 | 2022 | |
| Gilead Sciences, INC. | $121.38 | 2022 | |
| Genentech USA, INC. | $120.24 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Products, LP | $116.56 | 2023 | Symtuza |
| Btg International INC. | $111.75 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.06 | 2021 | |
| Dova Pharmaceuticals | $68.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $53.18 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $41.70 | 2022 | |
| Blueprint Medicines Corporation | $39.12 | 2021-2022 | |
| Acrotech Biopharma INC. | $25.27 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $24.66 | 2021 | |
| Genzyme Corporation | $21.81 | 2022 | |
| Sobi, INC | $20.87 | 2022 | |
| Pfizer INC. | $16.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jocelyn Mckeithan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.